Today we announced that clinical, safety and translational
Teona Gherasim
Today we announced that clinical, safety and translational data from our Phase 1/2 study evaluating mRNA-4359 in combination with pembrolizumab in checkpoint inhibitor-resistant/refractory (CPI-R/R) melanoma patients will be presented at the 2025 European Society for Medical https://t.co/OkHWy7fhzY
astăzi